VA Study: Diabetes Drug Cuts Addiction Risk for Veterans

Diabetes medications already known for weight loss might hold an unexpected superpower: fighting addiction itself.

A massive new study from the VA St. Louis Health Care System tracked over 606,000 veterans with type 2 diabetes and discovered something remarkable. Those taking GLP-1 drugs like Ozempic, Wegovy, and Mounjaro showed lower rates of developing substance use disorders involving alcohol, opioids, nicotine, cocaine, cannabis, and other substances.

The numbers tell a powerful story. For every 1,000 veterans using these medications over three years, researchers estimate seven cases of substance use disorder were prevented, along with 12 serious incidents like hospitalization, overdose, or death.

Among veterans already struggling with addiction, GLP-1 users faced fewer hospitalizations, overdoses, and deaths. The study also revealed a 25% drop in suicidal thoughts, easing earlier concerns that these drugs might increase suicide risk.

Dr. Ziyad Al-Aly, the study's senior author and chief of Research and Development at VA St. Louis, sees this as potentially transformative. Current addiction treatments work one substance at a time: nicotine patches for smoking, methadone for opioids, naltrexone for alcohol. Some substances like methamphetamine have no approved medications at all.

GLP-1 drugs appear to work differently. They target receptors in the brain's reward center, the same circuitry that addiction hijacks. Instead of addressing individual substances, these medications seem to quiet the underlying craving mechanism itself.

The Ripple Effect

The implications stretch far beyond the VA system. More than 48 million Americans live with substance use disorders, including a disproportionate number of veterans facing overlapping challenges of chronic pain, PTSD, and addiction.

While GLP-1s aren't yet approved for addiction treatment, the evidence is building fast. Multiple randomized controlled trials are underway, including one at the National Institute on Drug Abuse testing semaglutide for alcohol reduction.

Dr. Anna Lembke, a Stanford addiction medicine specialist, cautions that the drugs don't work identically for everyone and carry risks including gastrointestinal issues and kidney problems that need careful consideration. The current study shows association, not direct causation, and reflects a mostly older, white, male veteran population.

Still, this research from VA St. Louis adds to an impressive body of work. An earlier 2025 study from the same team examined GLP-1 effects across 175 health outcomes in over 2 million veterans, finding reduced risks for dementia, Alzheimer's, and seizures.

For veterans who've cycled through traditional addiction treatments without success, these findings offer something genuinely new: hope that one medication might address multiple addictions simultaneously, targeting the root of craving rather than its individual expressions.